CollPlant Biotechnologies announced on February 12, 2025, that it has been granted U.S. Patent No. 12,186,449, which relates to its photocurable dermal filler product candidate. This patent covers polymerizable solutions comprised of modified recombinant human collagen (rhCollagen) and other constituents, such as hyaluronic acid.
The patent provides intellectual property protection for key aspects of this innovative dermal filler technology, which is designed to offer both wrinkle-filling properties and the ability to regenerate skin tissue. This protection is secured until 2039.
This patent strengthens CollPlant's position in the medical aesthetics market, where its proprietary photocurable dermal filler is viewed as a potential game-changer for facial plastic surgery and long-lasting facial sculpting. The dermal filler market is valued at approximately $6.3 billion with a 10% CAGR.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.